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Abstract
Purpose: The purpose of this study was to evaluate the predictive value of 2-deoxy-2-[F-18]
fluoro-D-glucose-positron emission tomography (FDG-PET) following concurrent chemoradio-
therapy (CRT) on survival in patients with carcinoma of the oropharynx (OPC).
Methods: Eighteen patients with primary OPC who underwent PET pre- and post-CRT were
evaluated prospectively for survival. The prognostic performance of post-CRT PET and CT for
recurrence was compared.
Results: Patients with positive post-CRT PET exhibited significantly lower 2-year cause-specific
survival and disease-free survival (50% vs. 91%, PG0.05 and 0% vs. 83%, PG0.0001); however,
patients with positive post-CRT CT did not exhibit any significant difference (67% vs. 83%, P=
0.416 and 50% vs. 75%, P=0.070). Other factors, such as clinical and pre-CRT PET variables,
also did not indicate any significant difference. The accuracy of prediction of residual and local
recurrence for post-CRT PET and CT (local%/regional%) was 83%/94% and 83%/78%,
respectively.
Conclusion: OPC patients with positive post-CRT PET exhibit poor survival. The prognostic
accuracy of post-CRT PET is superior to that of CT. The results of post-CRT FDG-PET should
be included in the management of the OPC patients.
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Introduction
S
quamous cell carcinoma of the oropharynx (OPC) is the
most prevalent type of head and neck squamous cell
carcinoma (HNSCC) and is increasing gradually, most likely
due to the prolongation of the average life span and increases
in cigarette smoking and alcohol consumption [1, 2]. The
incidence in men is 2–5 times greater than that in women.
The incidence and death of pharyngeal cancer is about
11,800 and 2,180 people in 2007, respectively, but this
incidence varies markedly between countries [3].
The management of patients with OPC remains contro-
versial. The predominant treatment modalities consist of
surgery, radiation therapy (RT), and chemoradiotherapy
(CRT), individually or in combination [4–10]. Although
single-modality therapy with radiation or surgery can
achieve similar loco-regional control for the early stage,
patients with more advanced disease (stage III or IV) have
been treated with surgery followed by RT or CRT. The
survival figures for advanced-stage OPC have remained
moderate despite the use of radical combined modality
treatments. In recent meta-analysis for advanced OPC, tumor
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groups undergoing surgery with or without RT and RT with
or without neck dissection (ND). However, patients who
underwent surgery with or without RT exhibited a higher
rate of severe or fatal complications [9]. Recently, the utility
of concurrent CRT for OPC has been reported [10]. In terms
of complications, RT with CRT could become a first-line
treatment for OPC.
Outcome indicators in patients with HNSCC, including
OPC, have traditionally been derived from clinical and
pathologic features [11, 12]. The identification of additional
prognostic factors for survival may allow the development of
individualized strategies that lead to improved survival
outcomes. Recent reports have described that pre-treatment
positron emission tomography (PET) using 2-deoxy-[F-18]
fluoro-D-glucose (FDG) for HNSCC including OPC pre-
dicted loco-regional control and survival outcome [13–17].
However, a limited number of reports have assessed the
utility of post-CRT FDG-PET for HNSCC [18]. Herein, we
report the importance of post-CRT FDG-PET as a novel
prognostic indicator in patients with OPC.
Materials and Methods
Patients
Between March 2004 and April 2006, 24 consecutive patients with
histologically proven OPC who were referred for PET evaluation of
tumor metabolism were registered prospectively into a database.
Six patients with systemic metastasis (Stage M1; two patients) at
baseline investigation and who were treated with surgery (no
consent of CRT; four patients) were excluded. Eighteen patients
(14 men, four women; mean age±SD, 61.7±9.0 years) were
ultimately enrolled in this study. A summary of the patient and
tumor characteristics is summarized in Table 1. Written informed
consent was obtained for all study patients.
Concurrent CRT
External beam radiotherapy was administered to a total dose of
60 Gy in 30 fractions, delivered at five fractions per week for
6 weeks. Chemotherapy consisted of six cycles of cisplatin (20 mg/
m
2), docetaxel (10 mg/m
2) and 5-fluorouracil (1,000 mg/m
2).
Chemotherapy was administered during week 1 of radiotherapy.
Assessment of the Tumor on Pre- and Post-CRT
All twenty patients underwent laryngoscopy, gastroscopy, chest X-
ray, CT of the neck, and FDG-PET to assess the initial stage. Initial
staging and treatment decisions did not take into consideration the
results of the FDG-PET scan.
Six weeks after the completion of CRT, tumor restaging was
performed with laryngoscopy, CT of the neck, and FDG-PET. Re-
staging and additional treatment decisions did not take into account
the assessment of the FDG-PET scan.
CT Scans of Neck
All pre- and post-CRT CT scans of the neck with contrast medium
were acquired with helical scans in 5- to 10-mm slices. For the
purpose of analysis, residual disease was classified in a dichoto-
mous fashion as negative or positive, based on CT findings before
and after CRT according to the Response Evaluation Criteria In
Solid Tumors (RECIST) criteria [19]. A loco-regional post-CRT CT
visual score was documented as either positive (either local or
regional residual site) or negative (both local and regional non-
residual site) by RECIST.
FDG-PET scans
A total of 36 FDG-PET scans were performed at pre- and post-
CRT. Each patient fasted for at least 6 h before intravenous
Table 1. Demographic and clinical characteristics of this study population
(n=18)
Characteristics No. of patients
Gender, male/female 14/4
Age, years (range) 61.7±9.0 (48–78)
Site of primary tumor
Anterior wall 3
Lateral wall 11
Posterior wall 3
Superior wall 1
Histological grading
G1/G2/G3 8/5/5
TNM classification (AJCC 2002)
T1/T2/T3/T4 2/4/9/3
N0/N1/N2/N3 5/1/11/1
M0/M1 18/0
Stage I/II/III/IV 0/1/5/12
G1/G2/G3 well/moderately/poorly differentiated, TNM tumor-node metas-
tasis, AJCC American Joint Committee on Cancer
Fig. 1. Flow chart showing the distribution of the patients'
outcome. OPC squamous cell carcinoma of the oropharynx,
CRT chemoradiotherapy, CR complete response, PR partial
response, Rec recurrence, CDF continuous disease-free,
NED no evidence of disease, DOD died of disease.
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were performed 1 h after FDG injection using a dedicated scanner
(HeadtomeV/ SET2400 W, Shimadzu, Kyoto, Japan), with 32 rings
of bismuth germanate (BGO) detectors that simultaneously produ-
ces 63 slices 3.125 mm thick along a 20-cm longitudinal field. All
emission data were corrected for tissue attenuation by measure of
transmission scan with an external source of
68Ge–
68Ga. The
intrinsic resolution was 3.7 mm full width at half-maximum
(FWHM), and the sensitivity of the device was 7.3 cps/Bq cm
−3.
Whole-body scans required four bed positions and were recon-
structed using an iterative median root reconstruction algorithm.
High-resolution transaxial, coronal, sagittal, and maximal
intensity projection images were displayed on a linear gray scale
monitor. In pre-CRT PET assessment, the standardized uptake
value (SUV) of the highest pixel within each local and regional site
was calculated by dividing the decay-corrected maximal count of
tumor area by the injected dose of FDG per unit of body weight. A
loco-regional visual score (positive or negative) of FDG-PET was
documented for the post-CRT PET assessment. The negative score
indicated visually that there was no abnormal uptake at both the
local and regional sites and a positive score indicated abnormal
accumulation at either the local or regional site. All images were
analyzed by two experienced nuclear medicine physicians and a
consensus was reached away two readers in all patients.
Statistical Analysis
Kaplan–Meier analysis was used to evaluate survival. Cause-
specific survival (CSS) and disease-free survival (DFS) were
measured from the date of the pre-CRT PET scan to the date of
death due to disease. The log-rank test was used to assess the
correlation of the endpoints with the visual score of post-CRT PET
Fig. 2. Cause-specific survival (CSS) and disease-free survival (DFS) according to the loco-regional score in post-CRT PET
and CT scans. The patients with negative post-CRT PET had statistically superior CSS than patients with PET positive (a, P=
0.045). The positive post-CRT PET scan was a strong predictor of DFS (b, PG0.0001). However, negative correlations were
observed between post-CRT CT scan and survival (CSS and DFS) in OPC patients treated with concurrent CRT (c, P=0.416; d,
P=0.070).
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Age, T category, pre-CRT Local SUV, N category, pre-CRT
Regional SUV, TNM stage, Histological grade). P-values less than
0.05 were considered to be statistically significant. All calculations
were performed using Statcel software, version 2 (OMS Inc.,
Tokyo, Japan).
The positive predictive value (PPV), negative predictive value
(NPV) and diagnostic accuracy of conventional contrast-enhanced
CTandFDG-PETatpost-CRTforloco-regionalrecurrenceincluding
residualofdiseasewerecalculatedtoassessthepredictivepotentialof
these modalities.
Results
Response to CRT
Figure 1 shows the response to CRT at last follow-up. In the
eighteen OPC patients who were treated with concurrent
CRT, 12 patients are still alive, four died as result of the
disease and two died as a result of other primary cancers
(esophageal and pancreatic carcinoma). The median follow-
up for surviving patients was 24 months (range 9–37 months).
Nine patients exhibited no recurrence after CRT. In nine
additional patients, residual disease or recurrence was
confirmed histologically and required salvage therapy. Two
patients presented with local recurrence alone, five presented
with regional disease, one patient presented with local and
regional disease, and one patient presented with local
recurrence and distant metastasis. At 2 years, local control
was 78%, regional control was 72%, and CSS was 78%.
Patient Outcome
We evaluated the ability of pre- and post-CRT FDG-PET to
predictlong-termsurvival.Inunivariateanalysis,patientswitha
positive visual score of post-CRT FDG-PET exhibited signif-
icantlylower2-yearCSSandDFS(50%vs.91%,P=0.045and
0% vs. 83%, PG0.0001), but patients with a positive RECIST
score of the post-CRT CT scan did not exhibit a statistically
lower 2-year CSS and DFS (67% vs. 83%, P=0.416 and 50%
vs. 75%, P=0.070; Fig. 2). No other factors, clinical or pre-
CRT PET variables differed regarding survival.
Residual and Recurrence Predictive Performance
of Post-CRT FDG-PET and CT
The prognostic performance for post-CRT FDG-PET and
CT is summarized in Table 2. Comparing post-CRT FDG-
PET and CT findings for the assessment of recurrence at the
primary site (local recurrence), both imaging modalities did
not exhibit any false-positive results and three false-negative
findings in four cases. However, the positive findings were
found in different cases (Fig. 3). For those patients with
lymph node metastases (regional recurrence), contrast-
enhanced CT was false-positive in two cases, compared
with no false-positive FDG-PET findings. CT was false-
negative in two cases, compared with one case for FDG-PET
(Fig. 4). The overall accuracy of post-CRT FDG-PET and
CT in evaluating local recurrence was 83% and 83%
respectively, and 94% versus 78% for regional recurrence.
Discussion
The identification of prognostic factors for loco-regional
control and survival may allow the development of individ-
Fig. 3. Discrepancy between post-CRT PET and CT findings
in a 78-year-old male with OPC of the right lateral wall, tonsil,
treated with concurrent CRT. Local recurrence was con-
firmed histologically about 6 months later. A contrast-
enhanced CT scan resulted in false-negative findings. a In
post-CRT PET, strong uptake tracer was seen the right
lateral wall (arrow). b Post-CRT axial CT scan showed normal
to slight hypertrophy of the tonsil without contrast enhance-
ment (arrow), and histological specimen immediately after the
end of CRT indicated no evidence of disease.
Fig. 4. Discrepancy between PET and CT findings. A 48-
year-old female with OPC of the superior wall relapsed in the
right parapharyngeal site about 2 months later. A contrast-
enhanced CT resulted in false-negative findings. a Post-CRT
PET correctly identified the right parapharyngeal metastasis
(arrow). b Post-CRT axial CT scan showed an 8×7 mm lymph
node that was enhanced homogeneously (arrow) with no
evidence of metastasis.
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survival. CT and MRI are major imaging tools in the
management of patients with head and neck squamous cell
carcinoma. Recently, several studies have suggested that pre-
treatment FDG-PET could play such a role in HNSCC
patients [13, 20]. The importance of the post-CRT metabolic
response for loco-regional control and survival was reported
in esophageal, rectal, and lung cancer patients [21–23]. Our
multivariate analysis of the entire series of patients showed
that, in the case of OPC, post-CRT FDG-PET was an
independent prognostic factor for survival.
The current study confirmed that positive FDG-PET
imaging after CRT identified a subset of OPC patients with
poor prognosis. Elevated FDG uptake after CRT indicated
the need to treat with salvage therapy for local, regional, or
distant metastasis because of a strong correlation with DFS
(PG0.0001). The CSS indicated that even when OPC
patients with positive FDG-PET after CRT are treated with
additional salvage therapies, such as chemotherapy and
surgery, their outcome is still poor. Post-CRT CT also
tended to predict DFS and CSS, but this result was not
statistically significant. Post-CRT strategies for OPC patients
should be individualized not by conventional post-CRT CT
scan but by post-CRT FDG-PET scan.
In the current study, there was no difference of CSS and
DFS in the pre-CRT assessments. Many other studies have
supported the importance of pre-treatment assessment for
survival, including FDG-PET scan and TNM classification
[11–13, 20]. Several reasons can be considered for the lack
of correlation between the pre-CRT assessments and
prognosis. Firstly, our study had been biased against the
clinical staging because of a clinical feature of OPC that is
difficult in early detection. Secondly, the numbers of our
prospective samples were too small to assess the correlation
between pre-treatment indicators and survival. A larger scale
trial may be able to further investigate these correlations.
The prognostic accuracy of regional recurrence for post-
CRT FDG-PET was superior to that of CT scan (94% vs.
78%). The clinical utility of post-treatment FDG-PET for
regional disease has been reported by Porceddu et al. [24].
They indicated that HNSCC patients with negative PET
scans, approximately 12 weeks after CRT, did not require
surgery and could be observed safely. Our results for OPC
patients are compatible with their findings. Early surgical
treatment, such as neck dissection, should not be considered
in OPC patients with negative FDG-PET after CRT.
In conclusion, the predictive value of post-CRT FDG-
PET is superior to that of conventional CT scan in OPC
patients. The OPC patients with positive FDG-PET after
CRT exhibited poor survival. In contrast, negative PET
studies after CRT indicated good prognoses. The results of
post-CRT FDG-PET should be included in the management
of the OPC patients.
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